Abstract
Alzheimers disease (AD) is an irreversible progressive neurodegenerative disease, leading to severe incapacity and death. It is the most common form of dementia among older people. AD is characterized in the brain by amyloid plaques, neurofibrillary tangles, neuronal degeneration, aneuploidy and enhanced neurogenesis and by cognitive, behavioural and physical impairments. Inherited mutations in several genes and genetic, acquired and environmental risk factors have been reported as causes for developing the disease, for which there is currently no cure. Current treatments for AD involve drugs and occupational therapy, and future developments involve early diagnosis and stem cell therapy. In this manuscript, we will review and discuss the recent developments, limitations, problems and promises on AD, particularly related to aneuploidy, adult neurogenesis, neural stem cells (NSCs) and cellular therapy. Though adult neurogenesis may be beneficial for regeneration of the nervous system, it may underlie the pathogenesis of AD. Cellular therapy is a promising strategy for AD. Limitations in protocols to establish homogeneous populations of neural progenitor and stem cells and niches for neurogenesis need to be resolved and unlocked, for the full potential of adult NSCs to be realized for therapy.
Keywords: Amyloid, aneuploidy, cellular therapy, neurodegenerative diseases, pathogenesis, presenilin
Current Alzheimer Research
Title: Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises
Volume: 6 Issue: 6
Author(s): Philippe Taupin
Affiliation:
Keywords: Amyloid, aneuploidy, cellular therapy, neurodegenerative diseases, pathogenesis, presenilin
Abstract: Alzheimers disease (AD) is an irreversible progressive neurodegenerative disease, leading to severe incapacity and death. It is the most common form of dementia among older people. AD is characterized in the brain by amyloid plaques, neurofibrillary tangles, neuronal degeneration, aneuploidy and enhanced neurogenesis and by cognitive, behavioural and physical impairments. Inherited mutations in several genes and genetic, acquired and environmental risk factors have been reported as causes for developing the disease, for which there is currently no cure. Current treatments for AD involve drugs and occupational therapy, and future developments involve early diagnosis and stem cell therapy. In this manuscript, we will review and discuss the recent developments, limitations, problems and promises on AD, particularly related to aneuploidy, adult neurogenesis, neural stem cells (NSCs) and cellular therapy. Though adult neurogenesis may be beneficial for regeneration of the nervous system, it may underlie the pathogenesis of AD. Cellular therapy is a promising strategy for AD. Limitations in protocols to establish homogeneous populations of neural progenitor and stem cells and niches for neurogenesis need to be resolved and unlocked, for the full potential of adult NSCs to be realized for therapy.
Export Options
About this article
Cite this article as:
Taupin Philippe, Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises, Current Alzheimer Research 2009; 6 (6) . https://dx.doi.org/10.2174/156720509790147151
DOI https://dx.doi.org/10.2174/156720509790147151 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Drug Targets in Alzheimers Disease (Executive Editors: G. Munch and G. Stuchbury)]
Current Pharmaceutical Design The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design The Perils of Alzheimers Drug Development
Current Alzheimer Research Integrated System Pharmacology and <i>In Silico</i> Analysis Elucidating Neuropharmacological Actions of <i>Withania somnifera</i> in the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Recent Trends in the Management of Alzheimer’s Disease: Current Therapeutic Options and Drug Repurposing Approaches
Current Neuropharmacology Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design